Please wait a minute...
文章检索
预防医学  2018, Vol. 30 Issue (1): 12-15    DOI: 10.19485/j.cnki.issn2096-5087.2018.01.004
  论著 本期目录 | 过刊浏览 | 高级检索 |
HPV感染与不良妊娠结局的关系研究
周静, 欧荣英, 周美茜, 陈香娟, 包影, 张文淼
温州医科大学附属第一医院产科,浙江 温州 325000
Association between human papillomavirus infection and adverse pregnancy outcome
ZHOU Jing, OU Rong-ying, ZHOU Mei-qian, CHEN Xiang-juan, BAO Ying, ZHANG Wen-miao
Department of Obstetrics,the First Affiliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang 325000,China
全文: PDF(504 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 了解妊娠期女性人乳头瘤病毒(HPV)感染现状及其对妊娠结局的影响,为预防不良妊娠结局提供参考。方法 纳入2015—2017年4月在温州医科大学附属第一医院产科门诊建卡的1 679名孕妇,收集年龄、孕产次和妊娠结局等资料,采集宫颈细胞并应用导流杂交基因芯片技术检测HPV,分析HPV感染的影响因素及其对妊娠结局的影响。结果 调查孕产妇1 679人,其中HPV阳性527例,感染率为31.39%;感染组与未感染组首次性行为年龄、文化程度及吸烟史比较,差异均有统计学意义(P<0.05)。HPV感染组不良妊娠结局发生率为31.50%,高于未感染组的9.81%(P<0.05);高危型、低危型和混合型HPV感染组胎膜早破、新生儿呼吸道乳头瘤和其他不良妊娠结局发生率差异均无统计学意义(P>0.05)。多因素Logistic回归分析结果显示,感染HPV是发生不良妊娠结局的危险因素(OR高危型=4.194,95%CI:3.099~5.675;OR混合型=3.350,95%CI:1.630~7.735;OR低危型=1.771,95%CI:1.288~2.434),年龄、孕产次与是否发生不良妊娠结局均未见统计学关联(P>0.05)。结论 HPV感染是不良妊娠结局发生的危险因素,应加强HPV感染途径、危害和HPV疫苗接种的宣传教育及孕前、孕期筛查工作。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
周静
欧荣英
周美茜
陈香娟
包影
张文淼
关键词 人乳头瘤病毒妊娠期妊娠结局危险因素    
AbstractObjective To investigate the infection rate of human papillomavirus(HPV)among pregnant women,and to explore the effect of HPV infection on adverse pregnancy outcome. Methods A total of 1 679 pregnant women in hospital were collected for the research. The flow-through hybridization and genechip(HybriMax) method was used to detect the infection of HPV. Univariate analysis was used to analyze the factors affecting HPV infection in pregnant women. The binary logistic analysis was used to analyze risk factors affecting adverse pregnancy outcome. Results HPV infection rate was 31.39%(527/1 679),including 14.23%(239/1 679)of HR-HPV,15.54%(261/1 679)of LR-HPV and 1.61%(27/1 679)of mixed of HR-HPV and LR-HPV. Univariate analysis showed that there was significant difference in initial sex age,education level and smoking history between infection group and non-infection group,with statistical difference(P<0.05). The incidence rate of adverse pregnancy outcomes in infection group(31.50%) was significant higher than that of non-infection group(9.81%),with statistical difference(P<0.01). The incidence rate of premature rupture of fetal membranes,newborn respiratory papillomatosis and other adverse pregnancy outcomes among HR-HPV group,LR-HPV group and mixed group had no significant difference(P>0.05). Binary logistic regression analysis showed HR-HPV infection(OR=4.194,95%CI:3.099-5.675),LR-HPV infection(OR=1.771,95%CI:1.288-2.434)and mixed type infection(OR= 3.350,95%CI:1.630-7.735)were the risk factors affecting adverse pregnancy outcome(P<0.01),however,age and times of gestation had no statistical significance in the binary logistic analysis(P>0.05). Conclusion HPV infection was the risk factors for adverse pregnancy outcome,which indicated that screening work in pre-pregnancy and pregnancy,and persisting in early prevention,early detection and early treatment could reduce the incidence rate of adverse pregnancy outcome.
Key wordsHuman papillomavirus    Gestation period    Pregnancy outcome    Risk factor
收稿日期: 2017-07-12      修回日期: 2017-08-25      出版日期: 2018-01-04
中图分类号:  R714.2  
基金资助:国家自然科学基金(81373075)
通信作者: 张文淼,E-mail:mwzh63@126.com   
作者简介: 周静,硕士,副主任医师,主要从事产科方面工作
引用本文:   
周静, 欧荣英, 周美茜, 陈香娟, 包影, 张文淼. HPV感染与不良妊娠结局的关系研究[J]. 预防医学, 2018, 30(1): 12-15.
ZHOU Jing, OU Rong-ying, ZHOU Mei-qian, CHEN Xiang-juan, BAO Ying, ZHANG Wen-miao. Association between human papillomavirus infection and adverse pregnancy outcome. Preventive Medicine, 2018, 30(1): 12-15.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2018.01.004      或      http://www.zjyfyxzz.com/CN/Y2018/V30/I1/12
[1] HAN L,MAIMAITIMING T,HUSAIYIN S,et al. Comparative study of HPV16 integration in cervical lesions between ethnicities with high and low rates of infection with high-risk HPV and the correlation between integration rate and cervical neoplasia[J]. Exp Ther Med,2015,10(6):2169-2174.
[2] ALVAREZ R D,HUH W K,BAE S,et al. A pilot study of pNGVL4a-CRT/E7(detox)for the treatment of patients with HPV16+cervical intraepithelial neoplasia 2/3 (CIN2/3) [J]. Gynecol Oncol,2015,140(2):245-252.
[3] 何友梅,吴小芬,陶国芝. 宫颈上皮内瘤变患病危险因素分析[J]. 预防医学,2017,29(5):524-526.
[4] VERMA G,VISHNOI K,TYAGI A,et al. Characterization of key transcription factors as molecular signatures of HPV-positive and HPV-negative oral cancers[J]. Cancer Med,2017,6(3):591-604.
[5] NIYIBIZI J,ZANRE N,MAYRAND M,et al. The association between adverse pregnancy outcomes and maternal human papillomavirus infection:a systematic review protocol[J]. Syst Rev,2017,6(1):53-64.
[6] 廖琪. 妊娠期孕妇HPV病毒感染的分型及母婴妊娠结局的影响[J]. 中国性科学,2017,26(6):127-128.
[7] SSHELLER N M,PASTERNAK B,MØLGAARD-NIELSEN D,et al. Quadrivalent HPV vaccination and the risk of adverse pregnancy outcomes[J]. N Engl J Med,2017,376(13):1223-1233.
[8] NIYIBIZI J,ZANRE N,MAYRAND M H,et al. The association between adverse pregnancy outcomes and maternal human papillomavirus infection:a systematic review protocol[J]. Syst Rev,2017,6(1):53-63.
[9] 邓雅静,杜琳. 妊娠晚期HPV潜伏感染对妊娠的影响分析[J]. 中国性科学,2013,22(5):62-64.
[10] 王晋萍,李占辉. 孕期HPV感染对宫颈病变的发生率及感染的相关影响因素研究[J]. 中国实验诊断学,2016,20(7):1111-1112.
[11] SNYMAN L C,DREYER G,VISSER C,et al. The vaccine and cervical cancer screen project 2 (VACCS 2):Linking cervical cancer screening to a two-dose HPV vaccination schedule in the South-West District of Tshwane,Gauteng,South Africa[J]. S Afr Med J,2015,105(3):191-194.
[12] 姚成莲,程刚,胡秀美,等. 外来务工女性人乳头瘤病毒感染状况及其认知度调查[J]. 浙江预防医学,2012,24(12):64-66.
[13] 张丽华,常晓红,范亚丽,等. 2012—2015年妇科患者感染人乳头瘤病毒型别及相关因素分析[J]. 中国病原生物学杂志,2017,12(1):83-86.
[14] SKINNER S R,SZAREWSKI A,ROMANOWSKI B,et al. Efficacy,safety,and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years:4-year interim follow-up of the phase 3,double-blind,randomised controlled VIVIANE study[J]. Lancet,2014,384(9961):2213-2227.
[15] MERCKX M,LIESBETH W V,ARBYN M,et al. Transmission of carcinogenic human papillomavirus tyes from mother to child:a meta-analysis of published studies[J]. Eur J Cancer Prev,2013,22(3):277-285.
[16] 尹香花,石敏. 妊娠期人乳头状瘤病毒感染母婴传播及预后的研究进展[J]. 中国妇产科临床杂志,2015,16(3):286-288.
[17] CHO G J,MIN K J,HONG H R,et al. High-risk human papillomavirus infection is associated with premature rupture of membranes[J]. BMC Pregnancy Childbirth,2013,13(1):1-4.
[18] 秦博文,应佳,雷倩,等. 陕西省妇女既往生育史与末次妊娠早产的相关分析[J]. 中华流行病学杂志,2017,38(2):158- 162.
[1] 贾铭, 彭菊意, 刘星宇, 刘宇丹, 赵华. 心血管代谢性共病危险因素的Meta分析[J]. 预防医学, 2023, 35(9): 790-795.
[2] 朱家姝, 关素珍. 孕期应激性生活事件与不良妊娠结局关系的研究进展[J]. 预防医学, 2023, 35(7): 587-590.
[3] 张媛, 韩正风, 马艳. 老年人群肌少症危险因素的病例对照研究[J]. 预防医学, 2023, 35(6): 461-464.
[4] 丁承辉, 吴萃, 薛琨, 励晓红, 万金豹, 陈秋艳, 朱潇翔. 宝山区糖尿病高危人群筛查结果分析[J]. 预防医学, 2023, 35(6): 509-513.
[5] 黄文, 汤佳良, 陈康康, 黄敏钢, 陈奇峰. 绍兴市心血管疾病高危人群危险因素聚集分析[J]. 预防医学, 2023, 35(4): 298-302,330.
[6] 李改芳, 冯勤梅, 仇丽霞. 基于技术接受与使用统一理论2的妇科门诊就诊患者HPV疫苗接种行为研究[J]. 预防医学, 2023, 35(4): 295-297,326.
[7] 窦倩如, 黄翠敏, 曹霞, 樊利春. 海南省女性HPV疫苗相关知识和接种意愿调查[J]. 预防医学, 2023, 35(4): 359-364.
[8] 徐佳惠, 卢莎, 胡文胜. 组学技术在妊娠期高血压疾病发病机制及预测研究中的应用进展[J]. 预防医学, 2023, 35(1): 36-40.
[9] 江伟, 刘艳, 杜渐, 许玉洋, 车鑫仁, 王婧, 王骏, 张学潮, 顾雯雯, 张小平. 2017—2021年杭州市HPV疫苗疑似预防接种异常反应监测结果[J]. 预防医学, 2023, 35(1): 71-73,77.
[10] 何亚盛, 张红霞, 倪银, 朱越燕, 彭敏, 杨丹红. 急诊重症监护病房住院患者医院感染的预测模型研究[J]. 预防医学, 2022, 34(9): 919-922.
[11] 罗环, 梁婧, 张非若, 贾宁, 王忠旭, 王如刚. 北京市重型汽车零部件生产企业工人职业性肌肉骨骼疾患调查[J]. 预防医学, 2022, 34(8): 809-815.
[12] 张洁, 费方荣, 胡如英, 龚巍巍, 钟节鸣. 浙江省慢性病主要危险因素的归因疾病负担研究[J]. 预防医学, 2022, 34(6): 541-546,554.
[13] 石晶, 赵春艳, 张国峰. 通州区男大学生HPV疫苗认知及接种意愿调查[J]. 预防医学, 2022, 34(6): 571-576.
[14] 陈敏超, 吴春玲, 周建英. 慢性阻塞性肺疾病合并侵袭性肺曲霉病的危险因素研究[J]. 预防医学, 2022, 34(10): 1002-1006.
[15] 裴航, 马执彬, 廖继芸, 杨晨, 刘兴荣. 砷暴露与自然流产关联的流行病学研究进展[J]. 预防医学, 2022, 34(10): 1011-1014,1019.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed